Theratechnologies (NASDAQ:THTX - Get Free Report) was downgraded by stock analysts at Jones Trading from a "strong-buy" rating to a "hold" rating in a research report issued on Thursday, Marketbeat Ratings reports.
Theratechnologies Price Performance
THTX traded up $0.77 during midday trading on Thursday, reaching $3.13. 10,560,877 shares of the company's stock were exchanged, compared to its average volume of 860,785. The business's 50-day moving average price is $2.60 and its 200 day moving average price is $2.05. The stock has a market capitalization of $143.92 million, a PE ratio of -39.13 and a beta of 0.55. Theratechnologies has a 1-year low of $1.12 and a 1-year high of $3.20.
Institutional Trading of Theratechnologies
Hedge funds have recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new position in shares of Theratechnologies during the 4th quarter worth $27,000. Bank of America Corp DE increased its stake in Theratechnologies by 1,416.7% in the fourth quarter. Bank of America Corp DE now owns 16,487 shares of the company's stock valued at $30,000 after purchasing an additional 15,400 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in Theratechnologies during the fourth quarter worth about $33,000. BNP Paribas Financial Markets purchased a new position in Theratechnologies during the fourth quarter worth about $36,000. Finally, Stonepine Capital Management LLC purchased a new stake in Theratechnologies in the 1st quarter valued at about $36,000.
About Theratechnologies
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
See Also
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
